MedTrace Logo

Ketamine Trial for the Treatment of Depression

NCT02401139 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-03-30

No results posted yet for this study

Summary

This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.

Conditions

  • Unipolar Depression

Interventions

DRUG

Ketamine

DRUG

Placebo

Sponsors & Collaborators

  • University of Sydney

    collaborator OTHER

  • The University of New South Wales

    lead OTHER

Principal Investigators

  • Colleen K Loo, MBBS, MD · University of New South Wales

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-07-31
Completion
2015-09-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02401139 on ClinicalTrials.gov